![Wilfried van Langenaeker](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Marcel Borgers | M | 84 |
Université Libre de Bruxelles
| 30 years |
Jonathan Faull | M | 69 |
Université Libre de Bruxelles
| 35 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Hans Louis Jos de Winter | M | - |
Silicos SA
![]() Silicos SA Pharmaceuticals: MajorHealth Technology Silicos, founded in June 2005, is a chemo-informatics-based biotechnology company empowering proprietary multi-target virtual screening technologies for the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases, such as cancer, infectious diseases, central nervous system and immunodeficiency diseases. Silicos' proprietary virtual screening technology is based on a unique concept called Spectrophores™, which are descriptors representing all possible three-dimensional molecular properties involved in the binding of a drug to its receptor. Cosmos™ is Silicos' platform for the de novo design of new small molecules optimized towards one or multiple targets. | 7 years |
Piotr Tyranowski | M | - |
Université Libre de Bruxelles
| 4 years |
Bart de Moor | M | 63 |
Silicos SA
![]() Silicos SA Pharmaceuticals: MajorHealth Technology Silicos, founded in June 2005, is a chemo-informatics-based biotechnology company empowering proprietary multi-target virtual screening technologies for the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases, such as cancer, infectious diseases, central nervous system and immunodeficiency diseases. Silicos' proprietary virtual screening technology is based on a unique concept called Spectrophores™, which are descriptors representing all possible three-dimensional molecular properties involved in the binding of a drug to its receptor. Cosmos™ is Silicos' platform for the de novo design of new small molecules optimized towards one or multiple targets. | - |
Alain van Gelderen | M | 53 |
Université Libre de Bruxelles
| 6 years |
Gert Adam Irma Thijs | M | - |
Silicos SA
![]() Silicos SA Pharmaceuticals: MajorHealth Technology Silicos, founded in June 2005, is a chemo-informatics-based biotechnology company empowering proprietary multi-target virtual screening technologies for the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases, such as cancer, infectious diseases, central nervous system and immunodeficiency diseases. Silicos' proprietary virtual screening technology is based on a unique concept called Spectrophores™, which are descriptors representing all possible three-dimensional molecular properties involved in the binding of a drug to its receptor. Cosmos™ is Silicos' platform for the de novo design of new small molecules optimized towards one or multiple targets. | 7 years |
Johan van den Bossche | M | - |
Silicos SA
![]() Silicos SA Pharmaceuticals: MajorHealth Technology Silicos, founded in June 2005, is a chemo-informatics-based biotechnology company empowering proprietary multi-target virtual screening technologies for the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases, such as cancer, infectious diseases, central nervous system and immunodeficiency diseases. Silicos' proprietary virtual screening technology is based on a unique concept called Spectrophores™, which are descriptors representing all possible three-dimensional molecular properties involved in the binding of a drug to its receptor. Cosmos™ is Silicos' platform for the de novo design of new small molecules optimized towards one or multiple targets. | - |
Didier Georges | M | - |
Université Libre de Bruxelles
| 4 years |
Alain Kupchik | M | - |
Université Libre de Bruxelles
| 5 years |
Marc Hellemans | M | 51 |
Université Libre de Bruxelles
| 4 years |
Qiu Zhi Xue | M | 67 |
Université Libre de Bruxelles
| 3 years |
Daniel Grossmann | M | 53 |
Université Libre de Bruxelles
| 5 years |
Sophie Malarme-Lecloux | F | 53 |
Université Libre de Bruxelles
| 2 years |
Julie Josephine van Hemelryck | F | - |
Université Libre de Bruxelles
| 4 years |
Jean-François Hoffelt | M | 62 |
Université Libre de Bruxelles
| 1 years |
Robert Bury | M | - |
Université Libre de Bruxelles
| 4 years |
Pedro de Boeck | M | 59 |
Université Libre de Bruxelles
| 4 years |
Fabrizio Corradini | M | 57 |
Université Libre de Bruxelles
| 1 years |
Vincent Magnée | M | 53 |
Université Libre de Bruxelles
| 4 years |
Lucrezia A. Reichlin | M | 69 |
Université Libre de Bruxelles
| 14 years |
Muriel de Lathouwer | F | 51 |
Université Libre de Bruxelles
| 4 years |
Vicente Conde Viñuelas | M | - |
Université Libre de Bruxelles
| 3 years |
Filip Kegels | M | 58 |
Université Libre de Bruxelles
| 2 years |
Gaudiana Giusti | F | 61 |
Université Libre de Bruxelles
| 3 years |
Karel Victor Hubert Everaet | M | 59 |
Université Libre de Bruxelles
| 3 years |
Ann J. Barbier | M | 59 |
Université Libre de Bruxelles
| 3 years |
André Boulanger | M | - |
Université Libre de Bruxelles
| 4 years |
Alexandre Kech | M | - |
Université Libre de Bruxelles
| 29 years |
Christian Pierre B van Schoote | M | 59 |
Université Libre de Bruxelles
| 4 years |
Vincent Schobbens | M | 61 |
Université Libre de Bruxelles
| 6 years |
Etienne van de Kerckhove | M | 60 |
Université Libre de Bruxelles
| 4 years |
Marc Wahba | M | - |
Université Libre de Bruxelles
| 4 years |
Ugo Falcinelli | M | - |
Université Libre de Bruxelles
| 1 years |
Kristel Verleyen | F | 53 |
Université Libre de Bruxelles
| 3 years |
Axel Miller | M | 58 |
Université Libre de Bruxelles
| 5 years |
Olivier Roger J. Majérus | M | 62 |
Université Libre de Bruxelles
| 1 years |
Hennie R. Hoogenboom | M | - |
Université Libre de Bruxelles
| 4 years |
Jean-Philippe Waterschoot | M | 61 |
Université Libre de Bruxelles
| 4 years |
Harold Mechelynck | M | - |
Université Libre de Bruxelles
| 1 years |
Chris Baty | M | - |
Université Libre de Bruxelles
| 2 years |
Robert Kiss | M | - |
Université Libre de Bruxelles
| 3 years |
Yvan de Launoit | M | - |
Université Libre de Bruxelles
| 3 years |
Guy Mannaerts | M | - |
Silicos SA
![]() Silicos SA Pharmaceuticals: MajorHealth Technology Silicos, founded in June 2005, is a chemo-informatics-based biotechnology company empowering proprietary multi-target virtual screening technologies for the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases, such as cancer, infectious diseases, central nervous system and immunodeficiency diseases. Silicos' proprietary virtual screening technology is based on a unique concept called Spectrophores™, which are descriptors representing all possible three-dimensional molecular properties involved in the binding of a drug to its receptor. Cosmos™ is Silicos' platform for the de novo design of new small molecules optimized towards one or multiple targets. | - |
Robert P. Swinnen | M | - |
Université Libre de Bruxelles
| 4 years |
Marc Mommaerts | M | - |
Silicos SA
![]() Silicos SA Pharmaceuticals: MajorHealth Technology Silicos, founded in June 2005, is a chemo-informatics-based biotechnology company empowering proprietary multi-target virtual screening technologies for the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases, such as cancer, infectious diseases, central nervous system and immunodeficiency diseases. Silicos' proprietary virtual screening technology is based on a unique concept called Spectrophores™, which are descriptors representing all possible three-dimensional molecular properties involved in the binding of a drug to its receptor. Cosmos™ is Silicos' platform for the de novo design of new small molecules optimized towards one or multiple targets. | - |
Christian René Tang-Jespersen | M | 55 |
Université Libre de Bruxelles
| 2 years |
Karim Chouikri | M | 54 |
Université Libre de Bruxelles
| 4 years |
Erik M. van Mulligen | M | - |
Université Libre de Bruxelles
| 2 years |
Marc Josz | M | 66 |
Université Libre de Bruxelles
| 2 years |
Christian Leclercq | M | - |
Université Libre de Bruxelles
| 4 years |
Louis Martens | M | 62 |
Université Libre de Bruxelles
| 4 years |
Benjamin Gigot | M | - |
Université Libre de Bruxelles
| 6 years |
Jack Veuskens | M | - |
Université Libre de Bruxelles
| 3 years |
Jos Sluys | M | 61 |
Université Libre de Bruxelles
| 4 years |
Genco Sanli | M | - |
Université Libre de Bruxelles
| 4 years |
Statistics
Country | Connections | % of total |
---|---|---|
Belgium | 56 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Wilfried van Langenaeker
- Personal Network